Thyme Care Raises $125M, Valuation Tops $2 Billion
Key Points
- Thyme Care raised $125 million in Series E funding on Wednesday, doubling its valuation from Series D less than a year ago.
- The company's services reach more than 10.5 million people across all 50 U.S. states and manage more than $7 billion in oncology spend.
- Revenue surpassed $125 million last year, five times higher than the previous year, with the company now profitable and generating positive free cash flow.
With the funding secured, Shah stepped down as CEO in July to become executive chairman of a newly formed parent company called Thyme Companies. Brad Diephuis, who previously served as Thyme Care's president and chief operating officer, took over as CEO. Shah said Diephuis has been a significant driver of Thyme Care's business success, and this move allows Shah to focus on building additional businesses that will address disconnections in cancer care delivery, access, and payment.
Thyme Care has grown into a major player in oncology support. The company's services are available to more than 10.5 million people across all 50 U.S. states and manages more than $7 billion in oncology spend. Revenue surpassed $125 million last year, five times higher than the previous year, reflecting rapid expansion of its virtual navigation platform that helps patients navigate the fragmented cancer care system.
Read Next
Meta's $18 Billion Settlement Clears Path for AI Product Launches
12 hours ago
Palo Alto Networks CEO: $1 Trillion Cybersecurity Infrastructure Unprepared for AI
20 hours ago
The first initiatives under Thyme Companies' new structure focus on two critical oncology challenges. One will address cancer drug affordability by accelerating adoption of biosimilars—clinically equivalent drugs that function like generic drugs but for biologics. According to Shah, cancer-focused biosimilars have not delivered cost savings to patients as promised, and Thyme Companies will work with health plans and providers to find meaningful savings. The second focus will improve access and navigation within the clinical trial space, where Shah said enrollment challenges are limiting patient access to beneficial trials and slowing drug development.
Shah stated that Thyme Care is now profitable and generating positive free cash flow, which provides resources for future investments and acquisitions. He said the company does not have a "near-term viewpoint" on an initial public offering but will continue to evaluate public and private investment opportunities. The first of the new businesses under Thyme Companies is expected to launch later this year.
Related coverage: Meta's $18 Billion Settlement Clears Path for AI Product Launches
Thyme Care's growth trajectory and investor backing reflect broader recognition of the need to address fragmentation in cancer care delivery. The company was ranked No. 18 on the 2026 CNBC Disruptor 50 list. With nearly 10.5 million people now relying on its navigation platform and the company managing billions in oncology spend annually, expansion into adjacent areas of cancer care financing and clinical trial access positions Thyme Companies to address systemic inefficiencies that affect cancer patients nationwide.
What This Means
Thyme Care's expansion into drug affordability and clinical trial access signals investor confidence that vertical integration of cancer care services—navigation, payment, and drug access—can capture significant value. The biosimilar adoption focus directly addresses a $10+ billion annual gap between theoretical and realized savings. Expect other healthcare platforms to pursue similar multi-subsidiary models to address fragmentation.
Sources: CNBC and other international news outlets.
Disclaimer: This article was produced with AI assistance based on publicly available news sources. While we strive for accuracy, NewsOracle makes no warranty as to the completeness or accuracy of the information. Errors and omissions may occur. Readers should independently verify all information before acting on it. NewsOracle does not intend to defame any individual or organisation and accepts no liability for any loss or damage arising from reliance on this content. Content is for informational purposes only and does not constitute legal, financial, medical, or professional advice. All rights reserved. Unauthorised reproduction prohibited.
NewsOracle Editorial
The NewsOracle Tech Desk covers breaking technology news including AI, Apple, Google, Tesla, Meta, OpenAI and product launches.
Latest coverage: Healthcare
